BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 25609490)

  • 1. [Molecular biology of sarcoma and therapeutic choices].
    Dufresne A; Cassier P; Heudel P; Pissaloux D; Wang Q; Blay JY; Ray-Coquard I
    Bull Cancer; 2015 Jan; 102(1):6-16. PubMed ID: 25609490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Molecular targeted drugs for soft tissue sarcoma and neuroendocrine tumor].
    Kato S
    Nihon Rinsho; 2015 Aug; 73(8):1398-402. PubMed ID: 26281696
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Targeted treatment of rare connective tissue tumors and sarcomas].
    Cassier P; Pissaloux D; Alberti L; Ray-Coquard I; Blay JY
    Bull Cancer; 2010 Jun; 97(6):693-700. PubMed ID: 20497911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Molecular biology of soft-tissue sarcomas].
    Coindre JM
    Bull Cancer; 2010 Nov; 97(11):1337-45. PubMed ID: 21084242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Targeted therapy of sarcomas].
    Cassier PA; Dufresne A; El Sayadi H; Pissaloux D; Alberti L; Decouvelaere AV; Ranchere D; Ray-Coquard I; Blay JY
    Bull Cancer; 2008 Oct; 95(10):963-74. PubMed ID: 19004727
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [The importance of mutational status in prognosis and therapy of GIST].
    Comandone A; Boglione A
    Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Regorafenib: a guide to its use in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib and sunitinib.
    Lyseng-Williamson KA
    BioDrugs; 2013 Oct; 27(5):525-31. PubMed ID: 23975637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular pathobiology of gastrointestinal stromal sarcomas.
    Corless CL; Heinrich MC
    Annu Rev Pathol; 2008; 3():557-86. PubMed ID: 18039140
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy.
    Pantaleo MA; Nannini M; Di Battista M; Catena F; Biasco G
    Cancer Treat Rev; 2010 Feb; 36(1):63-8. PubMed ID: 19914780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics of rare mesenchymal tumors: implications for targeted treatment in DFSP, ASPS, CCS, GCTB and PEComa.
    Rutkowski P; Przybył J; Świtaj T
    Int J Biochem Cell Biol; 2014 Aug; 53():466-74. PubMed ID: 24704529
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Emerging drugs for the treatment of soft tissue sarcomas.
    Cassier PA; Dufresne A; Fayette J; Alberti L; Ranchere D; Ray-Coquard I; Blay JY
    Expert Opin Emerg Drugs; 2007 Mar; 12(1):139-53. PubMed ID: 17355219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ESMO: regorafenib improved PFS for GIST in post-imatinib/sunitinib setting.
    Oncology (Williston Park); 2012 Nov; 26(11):1072. PubMed ID: 23330348
    [No Abstract]   [Full Text] [Related]  

  • 13. Profiling of potential driver mutations in sarcomas by targeted next generation sequencing.
    Andersson C; Fagman H; Hansson M; Enlund F
    Cancer Genet; 2016 Apr; 209(4):154-60. PubMed ID: 26987750
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Molecular pathology of sarcomas.
    Osuna D; de Alava E
    Rev Recent Clin Trials; 2009 Jan; 4(1):12-26. PubMed ID: 19149759
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Value of pharmacokinetic studies for patients with gastrointestinal stromal tumors.
    De Giorgi U
    Future Oncol; 2013 Nov; 9(11):1675-7. PubMed ID: 23862700
    [No Abstract]   [Full Text] [Related]  

  • 16. Management of recurrent gastrointestinal stromal tumors.
    Winer JH; Raut CP
    J Surg Oncol; 2011 Dec; 104(8):915-20. PubMed ID: 21337345
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Antiangionic drugs in soft tissue sarcoma].
    Salas S; Huynh T; Deville JL; Duffaud F
    Bull Cancer; 2010 Jun; 97(6):701-5. PubMed ID: 20483703
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular classification of soft tissue sarcomas and its clinical applications.
    Jain S; Xu R; Prieto VG; Lee P
    Int J Clin Exp Pathol; 2010 Apr; 3(4):416-28. PubMed ID: 20490332
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Resistance and treatment strategy of gastrointestinal stromal tumor target therapy].
    Lu W; Lu WQ
    Zhonghua Wei Chang Wai Ke Za Zhi; 2012 Mar; 15(3):309-12. PubMed ID: 22454182
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Gastrointestinal stromal tumour.
    Rubin BP; Heinrich MC; Corless CL
    Lancet; 2007 May; 369(9574):1731-41. PubMed ID: 17512858
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.